2018-04-18 çååŠç ç©¶æ,倧éªå€§åŠ
çååŠç ç©¶æ(çç )çåœå»ç§åŠç ç©¶ã»ã³ã¿ãŒååå¶åŸ¡ç ç©¶ããŒã ã®é»åŽç¥åããŒã ãªãŒããŒ(倧éªå€§åŠå
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒç¹ä»»ææ(åžžå€))ã倧éªå€§åŠå
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒã®äŒå¢æžç¹ä»»åææ(åžžå€)ãã®å
±åç ç©¶ã°ã«ãŒãã¯ãç
åäœããã®ææé²åŸ¡ã«å¿
é ã®æäœ[1]ãäœãããçµè·¯ãæããã«ããŸããã
æ¬ç ç©¶ææã¯ã广çãªæäœã®ç£çãæšçã«ããæ°ããã¯ã¯ãã³éçºã«å€§ããè²¢ç®ãããšæåŸ
ã§ããŸãã
ä»åãå
±åç ç©¶ã°ã«ãŒãã¯ãããŠã¹ãçšããè§£æãè¡ãããŠã€ã«ã¹ãªã©ã®ç
åäœãçäœå
ããé€å»ããããã«å¿
èŠãªæäœååã®äžã§ããç
åäœãšã®èŠªåæ§ã®é«ãè¯è³ªãªæäœãã©ã®ãããªä»çµã¿ã§äœãããã®ããæããã«ããŸããããŠã€ã«ã¹ãªã©ã®å€æ¥ç°ç©ãäœå
ã«äŸµå
¥ãããšã掻æ§åããB现è[2]ããèäžå¿[3]ãšããåŸ®å°æ§é ã®äžã§ãé«èŠªåæ§ã®æäœãç£çããããã©ãºã现è[4]ããžãšååããŸããæ¬ç ç©¶ã§ã¯ãèäžå¿ã«ååšããB现èã詳ããè§£æããçµæããã©ãºã现èãžååããããšãéåœã¥ããããåé§çްèãåå®ããããšã«åããŠæåããŸããããŸãããã®åé§çްèã¯ãèäžå¿B现èãšæ¿Ÿèæ§ãã«ããŒT现è(Tfh现è)[5]ãšã®å®å®çãªçžäºäœçšã«ãã£ãŠèªçããããšãæããã«ããŸããããã®ãã©ãºã现èã®åé§çްèãå¹çè¯ãèªå°ããããšããæ°ããªã¯ã¯ãã³éçºã®ææšã«ãªããšèããããŸãã
æ¬ç ç©¶ææã¯åœéç§åŠéèªãImmunityãã«æ²èŒãããã®ã«å
ç«ã¡ããªã³ã©ã€ã³ç(4æ17æ¥ä»:æ¥æ¬æé4æ18æ¥)ã«æ²èŒãããŸãã
â»å ±åç ç©¶ã°ã«ãŒã
çååŠç ç©¶æ çåœå»ç§åŠç ç©¶ã»ã³ã¿ãŒ
ååå¶åŸ¡ç ç©¶ããŒã
ããŒã ãªãŒã㌠é»åŽ ç¥å(ãããã ãšãã²ã)
(倧éªå€§åŠ å
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒ ååå¶åŸ¡ç 究宀 ç¹ä»»ææ(åžžå€))
ç ç©¶å¡(ç ç©¶åœæ) 米谷 èå¹³(ãããã« ãããžã)
(çŸ äº¬éœå€§åŠ iPS现èç ç©¶æ ç¹å®æ ç¹å©æ)
çµç¹åæ
ç ç©¶ããŒã
ããŒã ãªãŒããŒ å²¡ç° å³°éœ(ããã ããã¯ã)
å»ç§åŠã€ãããŒã·ã§ã³ããæšé²ããã°ã©ã
å¥åº·å»çããŒã¿AIäºæž¬æšè«éçºãŠããã
ãŠããããªãŒã㌠å·äž è±è¯(ãããã¿ ããããã)
çåœæ©èœç§åŠç ç©¶ã»ã³ã¿ãŒ
现èã·ã¹ãã åæ
äºæž¬ç ç©¶ãŠããã
ãŠããããªãŒã㌠åå£ å
ä¹(ãããã¡ ãã€ãã)
(ç§åŠæè¡æ¯èæ©æ§(JST)ããããç ç©¶è
)
倧éªå€§åŠ å
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒ
ååå¶åŸ¡ç 究宀
ç¹ä»»åææ(åžžå€) äŒå¢ æž(ãã ããã)
ç¹ä»»æè¡è·å¡ äŒè€ ç¶Ÿå(ããšã ããã)
倧åŠé¢ç è€äº å¥å€ªé(ãµãã ããããã)
å
ç«å¿çãã€ããã¯ã¹ç 究宀
ææ éŽæš äžå(ããã ããã²ã)
ç²èå
ç«åŠ
ææ ç«¹ç° æœ(ããã ããã)
(倧éªå€§åŠå€§åŠé¢ å»åŠç³»ç ç©¶ç§ å
ç«å¶åŸ¡åŠ ææ)
KOTAIãã€ãªãã¯ãããžãŒãºæ ªåŒäŒç€Ÿ
代衚åç· åœ¹ å±±äž åç·(ããŸãã ããã)
â»ç ç©¶æ¯æŽ
æ¬ç ç©¶ã¯ãJSTæŠç¥çåµé ç ç©¶æšé²äºæ¥CRESTãæ¶²æ§å ç«å¶åŸ¡ã«ããæ°ããæ²»çæ³ã®éçº(ç 究代衚è :é»åŽç¥å)ãããããããçäœã·ã¹ãã çè§£ã»å»ç§åŠå¿çšãå®çŸãã1çŽ°èæ žé žèšæž¬æè¡ã®éçº(ç ç©¶è :åå£å ä¹)ããæéšç§åŠçç§åŠç ç©¶è²»è£å©éãæ¶²æ§å ç«èšæ¶ã®çæã»ç¶æã»æŽ»æ§åæ©åº(ç 究代衚è :é»åŽç¥å)ãããã¡ã¢ãªãŒB现èã®åœ¢æãšç¶æãæ¯ããå çã»å€çã¡ã«ããºã (ç 究代衚è :é»åŽç¥å)ãããé«èŠªåæ§ãã©ãºã现èã®éžæããã³çåç¶æãæ ãååæ©æ§ã®è§£æ(ç 究代衚è :äŒå¢æž)ããå é²å»è¬ç ç©¶æ¯è財å£ç ç©¶å©æãé«èŠªåæ§æäœãç£çãããã©ãºã现èã®èªå°ã»éžæã«é¢ããååæ©æ§ã®è§£æ(ç ç©¶è :äŒå¢æž)ãã®æ¯æŽãåããŠè¡ãããŸããã
èæ¯
è¿å¹Žãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®ææã«ãããæ¥æ¬åœå
ã ãã§ã幎é1,000人以äžãã®æ»è
ãåºãŠããŸã泚1)ããã®ããããŠã€ã«ã¹ã»çŽ°èææã«å¯Ÿããçäœé²åŸ¡ã¡ã«ããºã ãè§£æãã广çãªã¯ã¯ãã³ãéçºããããšãã瀟äŒçã«éèŠãªèª²é¡ãšãªã£ãŠããŸãã
ãŠã€ã«ã¹ã现èãªã©ã®å€æ¥ç°ç©ãç§ãã¡ã®çäœã«äŸµå
¥ãããšãå
ç«ç³»ã®çްèãæŽ»æ§åããç°ç©ãæé€ããããã®ç©è³ªãç£çããŸãããã®äžã§ãããšãããéèŠãªã®ãæäœã§ããæäœã¯ãB现èããååããããã©ãºã现èããšãã现èã«ãã£ãŠäœãããŸããããã©ãºã现èã«ã¯å€§ããåããŠ2çš®é¡ã®ã¿ã€ããååšããŸããäžã€ã¯ç°ç©ã«ãã£ãŠéããã«èªå°ãããã¿ã€ãã§ãç
åäœãšã®èŠªåæ§ã®äœãæäœãè¿
éã«ç£çããŸããããäžã€ã¯èäžå¿ãšããå Žæã§äœãããã¿ã€ãã§ãèŠªåæ§ã®é«ãè¯è³ªãªæäœãç£çããŸããèäžå¿ã«ååšããB现è(èäžå¿B现è)ã¯ãèªãã®æäœéºäŒåã«å€ç°ãç¹°ãè¿ãå°å
¥ããããšã§ãèªãã®æäœã®æ§èœãé«ããŠãããŸãããããŠã现èããŠã€ã«ã¹ãæ»æããããã®é«èŠªåæ§æäœãæã€ããã«ãªã£ãèäžå¿B现èãããã©ãºã现èãžãšååãããšèããããŠããŸããã
ãããã£ãŠãææé²åŸ¡ã«å¹æçãªãé«èŠªåæ§ã®è¯è³ªæäœãç£çããã¿ã€ãã®ãã©ãºã现èãã©ã®ãããªã¡ã«ããºã ã§èªçããã®ããæããã«ããããšãéåžžã«éèŠã§ããããããçäœå
ã«ããããã©ãºã现èã®æ°ãéåžžã«å°ãªãããè§£æãé£ããããšããŸããããŸã§ãèäžå¿ãçµãŠèªçãããã©ãºã现èãä»ã®ã¿ã€ãã®ãã©ãºã现èãšèå¥ããæ¹æ³ããªãã£ãããšãããååã®çµè·¯ã¯æããã«ãããŠããŸããã§ããã
泚1)åçåŽåç 人å£åæ
調æ»äººå£åæ
çµ±èšå¹³æ28幎第7衚
ç ç©¶ææ³ãšææ
å
±åç ç©¶ã°ã«ãŒãã¯ãŸããèäžå¿B现èã®äžã«ã¯ããã©ãºã现èãžã®ååãæ¢ã«å§ãŸã£ãŠãããã®ãååšããã®ã§ã¯ãªãããšèããŸãããèäžå¿B现èã¯ã転åå å[6]Bcl6[7]ãçºçŸããŠããŸããããã©ãºã现èãžååãããšBcl6ã®çºçŸã倱ããŸããããã§ãBcl6ã®çºçŸãèå
è²çŽ ã§è¿œè·¡ã§ããã¬ããŒã¿ãŒããŠã¹[8]ãçšããŠè§£æããŸããããããšãèäžå¿B现èã®äžéšã§Bcl6ã®çºçŸãäœäžããŠããããšãåãããŸãã(å³1)ããŸãããã®Bcl6ã®çºçŸãäœäžããŠããèäžå¿B现èã¯ãä»ã®èäžå¿B现èãšç°ãªãããã©ãºã现èãžã®ååã«å¿
é ã®è»¢åå åIRF4[9]ã匷ãçºçŸããŠããããšããŸã现è衚é¢ã«CD69ãšããååããŒã«ãŒãæã€ããšãèŠãã ããŸãããããã§ãBcl6ã®çºçŸãäœäžãCD69ãçºçŸããŠããããšããããã®èäžå¿B现èããBcl6loCD69hi现èããšåŒã¶ããšã«ããŸããã
ç¶ããŠãBcl6loCD69hi现èããæ¬åœã«ãã©ãºã现èã®åé§çްèã§ãããã©ãããæ€èšŒããŸããããŸããé»åŽããŒã ãªãŒããŒãã以åå ±åããèäžå¿B现èã®éåœè¿œè·¡ã·ã¹ãã [10] 泚2)ã䜿çšããŠãèäžå¿ç±æ¥ã®ãã©ãºã现èãåé¢ããèäžå¿B现èãšæäœéºäŒåã®é
åãæ¯èŒããŸããããã®çµæãBcl6loCD69hi现èãšèäžå¿ç±æ¥ãã©ãºã现èã®æäœéºäŒåã®é
åã䌌ãŠããããšãããBcl6loCD69hi现èããã©ãºã现èãžååãããšèããããŸããã
ãŸããBcl6loCD69hi现èã¯ãç
åäœãšã®èŠªåæ§ã®é«ãè¯è³ªãªæäœãçã¿åºãéºäŒåå€ç°ãå€ãæã€ããšãæãããšãªããŸãããããã«ãBcl6loCD69hi现èã¯èäžå¿B现èã«ç¹åŸŽçãªéºäŒåã®çºçŸã倱ã£ãŠããããšãéã«ãã©ãºã现èã«ç¹åŸŽçãªéºäŒåãçºçŸãå§ããŠããããšãæãããšãªããŸããããããã®çµæãããèäžå¿B现èã®äžã§ãBcl6loCD69hi现èã¯ããã©ãºã现èãžã®ååãéåœã¥ããããåé§çްèã§ãããšèããããŸãã
èäžå¿B现èããã©ãºã现èãžãšååããã«ã¯ãæ¿Ÿèæ§ãã«ããŒT现è(Tfh现è)ããã®ã·ã°ãã«ãå¿
èŠã§ããããšãç¥ãããŠããŸããå®éã«ãBcl6loCD69hi现èã§ã¯ãTfh现èããã®ã·ã°ãã«ããCD40[11]ãšããå容äœãä»ããŠãä»ã®èäžå¿B现èããã匷ãå
¥ã£ãŠããããšãåãããŸãããããã§ãèäžå¿B现èäžã§CD40ã¿ã³ãã¯è³ªã®çºçŸãæžå°ããããšããããã©ãºã现èãžã®ååãååçšåºŠã«æžå°ããŸãã(å³2)ããã®ããšãããTfh现èãä»ãããã«ãã·ã°ãã«[12]ã®éããã©ãºã现èãžã®ååãå¶åŸ¡ããŠããããšãåãããŸããã
ã§ã¯ããªããã©ãºã现èã®åé§çްèã¯ãTfh现èãã匷ããã«ãã·ã°ãã«ãåããããã®ã§ãããããBcl6loCD69hi现èã¯ãæ¥çååã§ããICAM-13[13]ãSLAM[14]ãä»ã®èäžå¿B现èãããå€ãçºçŸããå®éã«Tfh现èãšããå¹çè¯ãçµåã§ããããšãæããã«ãªããŸãã(å³3)ããã®Tfh现èãšã®çµåãé»å®³ãããšIRF4ã®çºçŸéãäœäžããBcl6loCD69hiçŽ°èæ°ãæžå°ããŸããã以äžã®çµæãããTfh现èãšBcl6loCD69hi现èã®å®å®çãªçžäºäœçšããèäžå¿B现èããã©ãºã现èã®åé§çްèãžãšèªå°ããã®ã«éèŠã§ããããšã瀺ãããŸãã(å³4)ã
泚2)Shinnakasu R et al. Regulated selection of germinal-center cells into the memory B cell compartment. Nat. Immunol.17 (2), 861-9, 2016
ä»åŸã®æåŸ
ã¯ã¯ãã³çæ³ã®ç®çã¯ã现èã»ãŠã€ã«ã¹ææã«æãæå¹ãªæäœãèªå°ããããšã§ããæ¬ç ç©¶ã¯é«èŠªåæ§ã®âè¯è³ªâãªæäœãç£çãããã©ãºã现èãèªå°ãããçµè·¯ãæããã«ããŸããããããã£ãŠãä»åã®ææãå¿çšããé«èŠªåæ§ã®æäœãã€ãããã©ãºã现èãå¹çè¯ãèªå°ããæ¹æ³ãéçºããããšããæ°ããã¯ã¯ãã³æŠç¥ã®äžã€ã®éµã«ãªããšæåŸ ã§ããŸãã
åè«ææ å ±
Wataru Ise, Kentaro Fujii, Katsuyuki Shiroguchi, Ayako Ito, Kohei Kometani, Kiyoshi Takeda, Eiryo Kawakami, Kazuo Yamashita, Kazuhiro Suzuki, Takaharu Okada and Tomohiro Kurosaki; “T follicular helper cell-germinal center B cell interaction strength regulates entry into plasma cell or recycling GC cell fate”, Immunity, DOI:10.1016/j.immuni.2018.03.027
çºè¡šè
çååŠç ç©¶æ
çåœå»ç§åŠç ç©¶ã»ã³ã¿ãŒ ååå¶åŸ¡ç ç©¶ããŒã
ããŒã ãªãŒã㌠é»åŽ ç¥å(ãããã ãšãã²ã)
倧éªå€§åŠ å
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒ ååå¶åŸ¡ç 究宀
ç¹ä»»åææ(åžžå€) äŒå¢ æž(ãã ããã)
å ±éæ åœ
çååŠç ç©¶æ åºå ±å®€ å ±éæ
åœ
倧éªå€§åŠ å
ç«åŠããã³ãã£ã¢ç ç©¶ã»ã³ã¿ãŒ (IFReC) äŒç»å®€
è£è¶³èª¬æ
-
- æäœ
- ãã©ãºã现èãç£çããã¿ã³ãã¯è³ªãç¹å®ã®ã¿ã³ãã¯è³ªãªã©æåãèªèããŠçµåããç¡æ¯å(äžå)ããåããæã€ã
-
- B现è
- å ç«çްèã®äžçš®ã现è衚é¢ã«ããB现èæåå容äœãšåŒã°ããã¿ã³ãã¯è³ªã§ãç åäœãªã©ã®æåãèªèããæäœãç£çãããB现èã¯ãæåã®åºæ¿ã«å¿ããŠèäžå¿B现èãèšæ¶B现èããã©ãºã现èãžãšååããã
-
- èäžå¿
- å ç«å¿çã®éã«ããªã³ãç¯ãèŸèãªã©ã®å ç«çµç¹ã«ãããŠèªå°ãããåŸ®å°æ§é ãèäžå¿ã§ã¯ãB现èãæŽ»çºã«å¢æ®ãããšãšãã«ãæäœéºäŒåã«å€ç°ãèµ·ãããããèŠªåæ§ã®é«ãæäœãã§ããã
-
- ãã©ãºã现è
- B现èãçµæ«ååãã现èã圢質现èãšãåŒã°ãããæäœ(å ç«ã°ãããªã³)ã®åæãšåæ³ã«ç¹åãã现èã
-
- æ¿Ÿèæ§ãã«ããŒT现è(Tfh现è)
- ãã«ããŒT现èã®äžçš®ãT现èé åããæ¿Ÿèãžç§»åããŠãB现èã®åããè£å©ã§ããããã«å€åããT现èã现è衚é¢ååãä»ããçžäºäœçšãããµã€ãã«ã€ã³ãšåŒã°ããæ¶²æ§å åãåæ³ããŠB现èã®åãã調ç¯ãããèäžå¿ã®èªå°ãšèäžå¿B现èã®éžæã«å¿ é ã
-
- 転åå å
- éºäŒåã®çºçŸã調ç¯ããã¿ã³ãã¯è³ªãå€ãã¯DNAãšã®çµåéšäœãæã€ãæšçéºäŒåã®èª¿ç¯é å(ããã¢ãŒã¿ãŒãªã©)ã«çµåããæšçéºäŒåã®çºçŸã掻æ§åããããã¯æå¶ããã
-
- Bcl6
- Bcl6ã¯è»¢åå åãšããŠæ©èœãããšèããããå€ãã®éºäŒåã®çºçŸå¶åŸ¡ã«é¢äžããŠãããç¹ã«ãBcl6ã¯èäžå¿B现èã®ååã«å¿ é ã§ãããèäžå¿B现èã¯Bcl6ãé«çºçŸããããèšæ¶B现èããã©ãºã现èã¯Bcl6ãçºçŸããªããBcl6ã¯B-cell lymphoma 6ã®ç¥ã
-
- ã¬ããŒã¿ãŒããŠã¹
- åçš®ã®ã€ã¡ãŒãžã³ã°ææ³ãªã©ãçšããŠéºäŒåçºçŸãã¢ãã¿ãŒã§ããããŠã¹ã
-
- IRF4
- IRF4ã¯å€ãã®éºäŒåã®çºçŸå¶åŸ¡ã«é¢äžãã転åå åãB现èãããã©ãºã现èãžã®ååã«å¿ é ã®å åã§ããããã©ãºã现èã§é«çºçŸããŠãããIRF4ã¯Interferon regulatory factor 4ã®ç¥ã
-
- èäžå¿B现èã®éåœè¿œè·¡ã·ã¹ãã
- èäžå¿B现èã¯ã¹ãã£ã³ãŽã·ã³1ãªã³é žå容äœ(S1pr2)ãçºçŸãããããã€ãŒãŽB现èãèšæ¶B现èããã©ãºã现èã¯S1pr2ãçºçŸããªããS1pr2-ERT2creãã©ã³ã¹ãžã§ããã¯ããŠã¹ã«ã¿ã¢ãã·ãã§ã³ãæäžããããšã§ãèäžå¿B现èããã³ããããååããèšæ¶B现èããã©ãºã现èãäžå¯éçã«ã©ãã«ããããšãå¯èœãšãªããèäžå¿B现èã®éåœã远跡ããããšãã§ããã
-
- CD40
- è «ç壿»å åã¬ã»ãã¿ãŒ(TNFR)ã¹ãŒããŒãã¡ããªãŒã®äžã€ã§ãå šãŠã®æçB现èã«çºçŸããååãCD40ã¯T现èã®CD154(CD40ãªã¬ã³ã)ãšçµåããB现èã«å¢æ€ãååãèªå°ããã·ã°ãã«ãäŒéããã
-
- ãã«ãã·ã°ãã«
- T现èãB现èãæŽ»æ§åããããã«äŒéããã·ã°ãã«ãT现èäžã®CD154(CD40ãªã¬ã³ã)ãT现èããç£çãããçš®ã ã®ãµã€ãã«ã€ã³(ã€ã³ã¿ãŒãã€ãã³4ãã€ã³ã¿ãŒãã€ãã³21ãªã©)ãB现èäžã®ãªã¬ã³ããã¬ã»ãã¿ãŒã«çµåããããšã«ãã£ãŠäŒéãããã
-
- ICAM-1
- å ç«ã°ãããªã³ã¹ãŒããŒãã¡ããªãŒã«å±ããæ¥çååãCD54ãšãåŒã°ããããªã³ãçãå ç®çްèãªã©å€ãã®çްèã«æåžžçã«çºçŸããŠãããICAM-1ã¯çŽ°èæ¥çååLFA-1(ãªã³ãçæ©èœé¢é£æå1)ãšçµåããççãå ç«å¿çã§ã®çްèéçžäºäœçšã«éèŠãªåœ¹å²ãæãããICAM-1ã¯Intercellular adhesion molecule 1ã®ç¥ã
-
- SLAM
- å ç«ã°ãããªã³ã¹ãŒããŒãã¡ããªãŒã«å±ãããCD150ãšãåŒã°ãããçžæã®çްèäžã®SLAMã«å¯Ÿãããªã¬ã³ããšããŠäœçšãããSLAMã®çºçŸã¯B现èãæš¹ç¶çްèãæŽ»æ§åT现èã«ã¿ãããB现èã®åºæ¿ã墿€èªå°ãã¢ãããŒã·ã¹ã®é»å®³ãªã©ã®æ©èœã«é¢äžããŠãããSLAM ã¯Signaling lymphocyte activation moleculeã®ç¥ã

å³1 èäžå¿B现èã«ååšããBcl6ã®çºçŸãäœäžããŠãã现è
Bcl6ãé»è²èå
è²çŽ (YFP)ã§æšèããBcl6-YFPã¬ããŒã¿ãŒããŠã¹ãæåã§å
ç«ããåŸã«è§£æãããšãããèäžå¿ã®æé å(Light zone, LZ)ã«ãBcl6-YFPã®çºçŸãäœãB现è(Bcl6lo现è)ãååšãã(å·Šã®èµ€æ å
)ãCD86ã¯LZ B现èãé«çºçŸãã现è衚é¢ååããã®Bcl6lo现èãåé¢ããŠéºäŒåçºçŸãè§£æãããšãããä»ã®èäžå¿B现èãšæ¯èŒããŠIRF4ã匷ãçºçŸããããšã倿ãã(å³ã®èµ€æ£)ã

å³2 èäžå¿(GC)B现èã®CD40çºçŸéãšãã©ãºã现èåå
CD40ãæ£åžžã«çºçŸããB现è(CD40+/+)ãšCD40ã®çºçŸãæžå°ãããB现è(CD40+/-)ã1:1ã®æ¯çã§ããŠã¹ã«ç§»å
¥ããæååºæ¿åŸããã©ãºã现èãžã®ååèœãæ¯èŒãããCD40ã®çºçŸãæžå°ããCD40+/-èäžå¿B现èã¯æ£åžžã«çåããããšãã§ããã(å·Š)ããã©ãºã现èãžã®ååèœã¯çŽååã«äœäžããŠãã(å³)ãCD45.1(X軞)ãšCD45.2(Y軞)ã¯çްè衚é¢ååã§ãCD40+/+现è(CD45.1+CD45.2-)ãšCD40+/-现è(CD45.1+CD45.2+)ãèå¥ããããã«æ€åºããã

å³3 èäžå¿B现èãšTfh现èã®çµåå¹ç
èäžå¿B现èãåé¢ããæåããããã®ååšäžãB现èãšTfh现èã®çµåãæ¯èŒãããä»ã®èäžå¿B现èãšæ¯èŒããŠãBcl6loCD69hi现è(èµ€æ£)ã¯Tfh现èãšããå¹çããçµåããããšãåãã£ãã

å³4ãè¯è³ªãªæäœãäœããã©ãºã现èãèªçããçµè·¯
èäžå¿B现è(é)ã®ãã¡Tfh现è(é»)ãšæç¶çã«çžäºäœçšãããã®ãBcl6loCD69hiIRF4+现è(ãã³ã¯)ãšãªãããã®åŸè¯è³ªãªé«èŠªåæ§æäœãäœãããã©ãºã现èãã«ååããã

